NU.V - NeutriSci International Inc.

TSXV - TSXV Delayed Price. Currency in CAD
0.0750
-0.0050 (-6.25%)
At close: 3:54PM EDT
Stock chart is not supported by your current browser
Previous Close0.0800
Open0.0800
Bid0.0750 x 0
Ask0.0800 x 0
Day's Range0.0750 - 0.0800
52 Week Range0.0650 - 0.2550
Volume177,000
Avg. Volume176,114
Market Cap8.443M
Beta (3Y Monthly)2.94
PE Ratio (TTM)N/A
EPS (TTM)-0.0220
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire26 days ago

    NeutriSci Enters Into LOI With Falcon Technologies Inc. dba Eco-Growth Strategies to Manufacture Sublingual CBD Products

    NeutriSci has agreed to enter into this LOI with Falcon to create sublingual tablets for the delivery of dietary supplements including CBD in which these tablets can potentially create a product that has more efficient absorption rates than other CBD products. Upon the successful completion of a due-diligence period, both companies will work towards signing a definitive agreement in early Q2/2019.

  • ACCESSWIRE26 days ago

    Falcon Technologies aka Eco-Growth Strategies Enters Into LOI With Neutrisci To Manufacture Sublingual CBD Products

    SACRAMENTO, CA / ACCESSWIRE / March 25, 2019 / Neutrisci International Inc. (the "Company" or "NeutriSci") (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9) the innovator and pioneer behind neuenergy®, and Falcon Technologies, Inc. ("Falcon") (FLCN:OTC PINK) are pleased to jointly announce they have entered into a Letter of Intent to create a sublingual CBD tablet. NeutriSci has agreed to enter into this LOI with Falcon to create sublingual tablets for the delivery of dietary supplements including CBD in which these tablets can potentially create a product that has more efficient absorption rates than other CBD products.

  • GlobeNewswire2 months ago

    Neutrisci Announces Product Sales Increase

    Neutrisci International Inc. (the "Company" or "NeutriSci") (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9) the innovator and pioneer behind neuenergy®, is pleased to announce that it has received its first order for its sublingual cannabidiol (CBD) tablets. This initial order will result in the Company reporting six figure sales for the current quarter. The quick dissolving, flavoured tablets are manufactured using the Company’s patent pending technology and offer a method to provide the consumer with a measured dose of known CBD product.

  • GlobeNewswire4 months ago

    NeutriSci Announces Exclusive Licensing Agreement for CBD Tablet Manufacturing & Distribution With LaSanta Botanicals Ltd.

    VANCOUVER, British Columbia, Dec. 06, 2018 -- NeutriSci International Inc. (the "Company" or "NeutriSci") (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9) the innovator and pioneer.